Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD). We surveyed NASH therapies currently in development, and found a significant variety of targets and approaches. Evaluation and clinical testing of these targets is an expensive and time-consuming process. Systems biology approaches could enable the quantitative evaluation of the likely efficacy and safety of different targets. This motivated our review of recent systems biology studies that focus on the identification of targets and development of effective treatments for NASH. We discuss the potential broader use of genome-scale metabolic models and integrated networks in the validation of drug targets, which could facilitate more productive and efficient drug development decisions for the treatment of NASH.

非酒精性脂肪性肝炎（NASH）是非酒精性脂肪肝疾病（NAFLD）的一种严重形式。我们调查了当前正在开发中的NASH治疗方法，发现了各种各样的目标和方法。对这些目标进行评估和临床测试是一个昂贵且耗时的过程。系统生物学方法可以实现对不同靶标可能的功效和安全性的定量评估。这激发了我们对最近系统生物学研究的回顾，这些研究着重于确定NASH的靶标和开发有效的治疗方法。我们讨论了在验证药物靶标方面可能更广泛地使用基因组规模的代谢模型和集成网络，这可以促进用于NASH治疗的更具生产力和效率的药物开发决策。